发布求助
文献互助 智能选刊 最新文献

Managed Care最新文献

筛选
英文 中文
FDA's Gottlieb Aims To End Biosimilars Groundhog Day. FDA的Gottlieb旨在结束土拨鼠日的生物仿制药。
Managed Care Pub Date : 2019-01-01
Richard Mark Kirkner
{"title":"FDA's Gottlieb Aims To End Biosimilars Groundhog Day.","authors":"Richard Mark Kirkner","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The FDA commissioner has an 11-step \"action plan\" to get biosimilars out of a repeat mode of unrealized potential. But issues like interchangeability still need clarifying if biosimilars are to have a major effect on drug expenditures.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 1","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37067435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity. 与Gary Lyman博士的对话:生物仿制药和治疗癌症治疗的经济毒性的研究。
Managed Care Pub Date : 2019-01-01
Peter Wehrwein
{"title":"A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.","authors":"Peter Wehrwein","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lyman has emerged as an important voice about biosimilars and their potential for corralling cancer costs. It's personal because Lyman is all too aware of how the price of medications can ruin patients financially. We need more biosimilars on the market, he contends.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 1","pages":"12-15"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37067438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be. 为什么生物仿制药永远不可能与原药相同，为什么它们不需要相同。
Managed Care Pub Date : 2019-01-01
Thomas Reinke
{"title":"Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be.","authors":"Thomas Reinke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The FDA's approval criteria require a biosimilar to be highly similar to its original biologic and show \"no clinically meaningful differences.\" But mere similarity is not close enough for many clinicians and some patients; it makes biosimilars seem riskier than the original biologics.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 1","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37067439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bringing Humira (Its Price) Down a Peg. 降低修美乐(Humira)的价格。
Managed Care Pub Date : 2019-01-01
Susan Ladika
{"title":"Bringing Humira (Its Price) Down a Peg.","authors":"Susan Ladika","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>It's the best-selling drug by revenue worldwide and manufacturer AbbVie has worked hard to fend off competition. Very hard. Humira faces competition in Europe, but it will probably take years before its market share is challenged in the United States.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 1","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37067436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Show Us (the U.S.) the Savings. 让我们(美国)看到储蓄。
Managed Care Pub Date : 2019-01-01
Thomas Reinke
{"title":"Show Us (the U.S.) the Savings.","authors":"Thomas Reinke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Companies with originator biologics on the market have used a variety of regulatory and legal tricks to fend off biosimilars and keep the revenue generated by their products pouring in. The most common approach has been for the \"originators\" to take legal action to assert or defend the patents attached to their products.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 1","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37067437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why the ACA is 'not dead yet' and lives on in 2019. 为什么ACA“还没死”，并在2019年继续存在。
Managed Care Pub Date : 2018-12-01
Robert Calandra
{"title":"Why the ACA is 'not dead yet' and lives on in 2019.","authors":"Robert Calandra","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The ACA-and more specifically, the individual ACA exchange market-is doing quite well these days, thank you very much. ACA premium prices have stabilized and even gone down for many plans. In October, CMS announced that the average premium for the second-lowest-cost silver plans for 2019 had decreased by 1.5%.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"27 12","pages":"20-21"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36844116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why the new opioid bill won't really change the way insurers approach the epidemic. 为什么新的阿片类药物法案不会真正改变保险公司处理这种流行病的方式。
Managed Care Pub Date : 2018-12-01
Frank Diamond
{"title":"Why the new opioid bill won't really change the way insurers approach the epidemic.","authors":"Frank Diamond","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Not that plans won't be taking a close look at some innovative approaches such as addiction recovery medical homes. One model includes bundled payments and performance bonuses, nationally recognized quality metrics, and the placement of treatment and recovery providers close to where patients with substance use disorder live.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"27 12","pages":"29-30"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36844117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Health Service Organizations: Managed Care Gets a New 4-Wheel Drive Vehicle To Navigate the Value-based Terrain. 人口健康服务组织:管理式护理获得了一种新的四轮驱动车辆，以导航基于价值的地形。
Managed Care Pub Date : 2018-12-01
Richard G Stefanacci, Terri Schieder
{"title":"Population Health Service Organizations: Managed Care Gets a New 4-Wheel Drive Vehicle To Navigate the Value-based Terrain.","authors":"Richard G Stefanacci,&nbsp;Terri Schieder","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Population health service organizations (PHSOs) are supplanting management service organizations that gained popularity in the '90s. PHSOs are emerging as the organizations within health systems that can improve the clinical and financial outcomes of the populations the health systems serve.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"27 12","pages":"38-39"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36844125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why marijuana is headed for the mainstream. 为什么大麻正在走向主流。
Managed Care Pub Date : 2018-12-01
Thomas Reinke
{"title":"Why marijuana is headed for the mainstream.","authors":"Thomas Reinke","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The credibility of cannabis as a source of a legitimate pharmaceutical ingredient in prescription medications took a major step forward in 2018 when the FDA approved Epidiolex (cannabidiol) for two types of severe seizures. Epidiolex was a stellar candidate for approval. It reduced convulsive seizures by about 40% and has a good safety profile.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"27 12","pages":"31"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36844121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why Medicare Advantage enrollment will keep on growing, whatever the politics. 为什么联邦医疗保险优惠计划的注册人数会持续增长，不管政治如何。
Managed Care Pub Date : 2018-12-01
Timothy Kelley
{"title":"Why Medicare Advantage enrollment will keep on growing, whatever the politics.","authors":"Timothy Kelley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In 2019, a record 36% of Medicare beneficiaries will be getting their benefits in a Medicare Advantage plan. CMS has broadened the services such plans can provide-services that may reduce expensive treatments and injuries. Insurers continue to see the market as a business opportunity. Critics see a slow-motion privatization of the entitlement.</p>","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"27 12","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36844111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书